The recent discoveries of euchromatic histone lysine methyltransferase 2 (EHMT2) and methyl-CpG binding domain protein 2 (MBD2) as novel epigenetic targets in T-ALL [91,92,93], together with CXCL12, will drive a new wave of epigenetic targeting molecules for further clinical investigation in T-ALL. This evidence concerns the gene MBD2 and acute lymphoblastic leukemia.